₩7,088,456
구입 가능 여부는 고객센터에 문의하십시오.
추천 제품
제품명
CHIRALPAK® HSA HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4 mm
material
stainless steel column
Quality Level
Agency
suitable for USP L79
제품 라인
CHIRALPAK®
포장
pkg of 1 ea
제조업체/상표
CHIRALPAK®
파라미터
137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.
기술
HPLC: suitable
길이 × I.D.
15 cm × 4 mm
Matrix
fully porous particle
기질 활성군
human serum albumin phase
입자 크기
5 μm
작동 pH
2-8
분리 기술
chiral
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
법적 정보
CHIRALPAK is a registered trademark of Daicel Corp.
가장 최신 버전 중 하나를 선택하세요:
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
